COL1A1 as a potential new biomarker and therapeutic target for type 2 diabetes

[Display omitted] •Col1a1 was linked to the hypoglycemic activity for the first time.•Alterations of jejunum total protein were analyzed by TMT-based proteomics.•EPO showed hypoglycemic effect via PI3K/AKT and ECM receptor interaction pathways. Type 2 diabetes (T2D) is a public health problem with a rising incidence worldwide. In this study, a potential new biomarker for T2D and mechanisms underlying the hypoglycemic effects of Enteromorpha prolifera oligosaccharide were investigated. Tandem mass tag labeling with LC–MS/MS was used to identify the differentially expressed proteins (DEPs) between the jejunum of diabetic rats and control rats. Correlations between glycometabolic parameters and DEPs were revealed by a network analysis. The expression levels of target genes in key metabolic pathways were further evaluated to identify candidate biomarkers. Among 6810 total proteins, approximately 88 % were quantified, of which 148 DEPs with a fold change of 1.2 and a corrected p-value of